Chai Discovery

Summary active Updated Jul 19, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location San Francisco, California
Founded 2024
Latest Stage Series C
Total Raised USD ~570M
Website https://chaidiscovery.com
Sector
ai biotech drug-discovery healthcare

Investors

Sunil Dhaliwal Seed (2024)
Ian Hathaway Seed ($30M, co-led) (2024)
Ali Partovi Seed (2024)
Miles Grimshaw Board role (2025)
Brad Lightcap Seed ($30M, co-led) (2024)
Index Ventures series-c (2026)
Kleiner Perkins series-c (2026)
Sequoia Capital series-c (2026)
Battery Ventures series-c (2026)
Thrive Capital series-c (2026)
Menlo Ventures series-c (2026)
General Catalyst series-c (2026)
OpenAI Startup Fund series-c (2026)
amplify-partners Seed (2024)
Neo Seed (2024)

Founders

Joshua Meier CEO & Co-Founder
Jack Dent Co-Founder
Matthew McPartlon Co-Founder
Jacques Boitreaud Co-Founder

About

Chai Discovery is a San Francisco AI-for-drug-discovery startup founded in 2024 by Joshua Meier, Jack Dent, Matthew McPartlon, and Jacques Boitreaud. The company builds AI models to predict and reprogram molecular interactions to accelerate pre-clinical drug discovery, and says its models are already deployed at large pharmaceutical partners including Lilly, Novartis, and Pfizer 1 2.

Funding History

Date Round Amount Lead Co-investors
2026-07-14 Series C USD 400M Index Ventures Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, Yosemite 1 2 3

The Series C set a USD 3.8B valuation, roughly triple Chai’s prior valuation from seven months earlier 3.

What Investors Say

Nina Achadjian, Index Ventures: “Chai has both [technical brilliance and commercial clarity]. They’re already there, with deployments already at the world’s largest pharma companies.” 1

Ilya Fushman, Kleiner Perkins: “The speed at which this team is advancing the frontier, technically and commercially, is remarkable.” 1

What Founders Say

Joshua Meier, CEO: “Tomorrow’s medicines should be designed with the precision, speed and scale of modern engineering, and this support helps us move faster towards that future.” 1

Sources

  1. Yahoo Finance, “Chai Discovery Announces $400M Series C to Advance AI-Driven Molecular Design,” July 14, 2026. Accessed July 2026. https://ca.finance.yahoo.com/news/chai-discovery-announces-400m-series-130000731.html↩↩↩↩↩

  2. Fierce Biotech, “Chai brews up $400M series C to fuel AI molecule models used by Lilly, Novartis and Pfizer,” July 2026. Accessed July 2026. https://www.fiercebiotech.com/biotech/chai-brews-400m-series-c-fuel-ai-used-lilly-novartis-and-pfizer↩↩

  3. Endpoints News, “Chai Discovery gets $400M, tripling valuation from seven months ago,” July 2026. Accessed July 2026. https://endpoints.news/chai-discovery-gets-400m-tripling-valuation-from-seven-months-ago/↩↩